Antiviral Drugs Market - Snapshot
Antiviral drugs refer to those prescription medicines that are capable of fighting against flu viruses in one’s body. Antiviral drugs could include intravenous solutions, an inhaled powder, liquid, or pills. However, antiviral drugs cannot be purchased just over-the-counter, one would need a prescription for obtaining such drugs. The global antiviral drugs market is likely to observe considerable growth due to the rising incidences of viral infections.
As coronavirus spreads at an exponential rate and the number of deaths crosses 74,000 worldwide, efforts are being made to lessen transmission through standard public health interventions. These interventions are based on tracing of contacts and isolation of cases. So far, there is no drug or vaccine to contain the spread of the pandemic worldwide. However, researchers and doctors have observed that antiviral drugs administered shortly after the onset of symptoms can diminish the infectiousness to others through diminished viral shredding in the patient’s respiratory secretions. The global antiviral drugs market is predicted to observe immense opportunity in the exponential spread of coronavirus. Besides, novel antiviral drugs, Tilorone and Remdesivir, have already come up as two of the most promising drugs for COVID-19 treatment, according to the researchers.
Rise in the Prevalence of Chronic Diseases to Support Demand of these Drugs
Rise in the research and development activities for development of newer and more advanced formulations is likely to further drive the demand for antiviral drugs in the near future. Many serious diseases could cause viral infections as their side effects. Such viral infection causing diseases are
As such, increased prevalence of these diseases are likely to increase the prevalence of viral infections thereby driving the demand for antiviral drugs. Apart from that, presence of sound healthcare infrastructure in several parts of the world is predicted to foster growth of the global antiviral drugs market in the years to come.
Global Antiviral Drugs Market – Overview
In recent years, there has been a considerable demand for antiviral drugs all across the globe. A large number of people are relying on these drugs to treat several diseases. A few years ago, the same population base relied on home remedies to cure basic diseases and infections. This kept these antiviral drugs market developing at a sluggish rate. However, in the past few years, technological advancements as well as advancements in the medical sciences have created a huge availability of these drugs. Previously, antiviral drugs were some sort of luxury. But with these developments, the production rate doubled up and these medicines became easily accessible to common masses. Naturally, the reliance over home remedies and cure dwindled as there came the availability of medically proven, more effective drugs. Furthermore, with the mass production or availability of these antiviral drugs, they also become cost effective. This only added to their popularity. Thus, the global antiviral drugs market has experienced a tremendous growth in recent years.
A new research report by Transparency Market Research on the global antiviral drugs market provide all the necessary insights and information required for formulation precise marketing strategies. According to the research report, the global market for antiviral drugs will exhibit a healthy CAGR of 6.40% over the course of the given forecast period of 2016 to 2024. The market is projected to reach a valuation worth US$82.9 bn by the end of the forecast period in 2024.
Targeted Efforts towards Better Global Healthcare to Drive Market Growth
There are various reasons behind getting infected by a viral infections. At times, the infection may also be a side effect of some other medical treatment. Viral infections are common side effect of the treatment for diseases such as respiratory disorders, HIV, diabetes, and cancer among others. Because of the growing prevalence of these major diseases, there has been a growing demand for antiviral drugs. Naturally, this has helped in pushing the growth of the global antiviral drugs market to newer heights. In addition to this, with economical, sociological, and technological advancements, considerable efforts have been made towards achieving a strong and robust healthcare infrastructure across the globe. Though we are far from perfection, we can take solace in the fact that these consolidated and targeted efforts are only expected to grow in the future. This has had a profound impact on the development of the global antiviral drugs market. With targeted efforts from organizations such as Red Cross and World Health Organization, the spread and reach of antiviral drugs has grown exponentially and has thus helped in the overall growth of the global market.
Early Availability of New Drugs is Pushing Growth of North America Market
In terms of geographical segmentation, the global market for antiviral drugs is divided into five key regions viz. Asia Pacific, Middle East and Africa, North America, Europe, and Latin America. Of these, the growth of the market is maximum in North America. The presence of strong healthcare infrastructure and early access to latest medications and medical technology are some of the key factors for the growth of the antiviral drugs market in North America. Moreover, several new drugs are already in the production pipeline that will further strengthen the growth of the regional market.
Asia Pacific and Africa regions are showing great promise for the development of their respective antiviral drugs market. Growing prevalence of viral diseases such as malaria, dengue, chikungunya, and other deadly viral diseases is prompting an ever increasing demand for these antiviral drugs from these regions.
Some of the key players in the global antiviral drugs market include names such as Merck & Co. Inc., Johnson and Johnson, Schering-Plough Corporation, AbbVie Inc., and AstraZeneca Plc. among others.
The global antiviral drugs market is segmented as follows:
|
By Disease Indication |
|
|
By Product Type |
|
|
By Distribution Channels |
|
|
By Geography |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Antiviral Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Antiviral Drugs Market Analysis and Forecasts, 2014–2024
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Market Outlook
4.8. Antiviral Drugs: FDA Approvals and Patent Expiries by each drug class
4.9. Global relative prevalence rate of each hepatitis genotype infection
4.10. Global relative prevalence rate of HIV infection
4.11. Pipeline Analysis: Major Market Players
5. Global Antiviral Drugs Market Analysis and Forecasts, By Disease Indication
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast by Disease Indication, 2014–2024
5.4.1. Hepatitis Virus Infection
5.4.2. HIV Infection
5.4.3. Respiratory Virus Infection
5.4.4. Others
5.5. Market Attractiveness by Disease Indication
6. Global Antiviral Drugs Market Analysis and Forecasts, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value Forecast by Product Type, 2014–2024
6.4.1. Branded Drugs
6.4.2. Generic Drugs
6.5. Market Attractiveness by Product Type
7. Global Antiviral Drugs Market Analysis and Forecasts, by Distribution Channels
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value Forecast by Distribution Channels, 2014–2024
7.4.1. Hospital Pharmacy Store
7.4.2. Retail Pharmacy Store
7.4.3. Online Pharmacy
7.5. Market Attractiveness by Distribution Channels
8. Global Antiviral Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market Value Forecast by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East and Africa
8.4. Market Attractiveness by Country/Region
9. North America Antiviral Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Key Trends
9.2. Market Value Forecast by Disease Indication, 2014–2024
9.2.1. Hepatitis Virus Infection
9.2.2. HIV Infection
9.2.3. Respiratory Virus Infection
9.2.4. Others
9.3. Market Value Forecast by Product Type, 2014–2024
9.3.1. Branded Drugs
9.3.2. Generic Drugs
9.4. Market Value Forecast by Distribution Channels, 2014–2024
9.4.1. Hospital Pharmacy Store
9.4.2. Retail Pharmacy Store
9.4.3. Online Pharmacy
9.5. Market Value Forecast by Country, 2014–2024
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disease Indication
9.6.2. By Product Type
9.6.3. By Distribution Channels
9.6.4. By Country
10. Europe Antiviral Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Key Trends
10.2. Market Value Forecast by Disease Indication, 2014–2024
10.2.1. Hepatitis Virus Infection
10.2.2. HIV Infection
10.2.3. Respiratory Virus Infection
10.2.4. Others
10.3. Market Value Forecast by Product Type, 2014–2024
10.3.1. Branded Drugs
10.3.2. Generic Drugs
10.4. Market Value Forecast by Distribution Channels, 2014–2024
10.4.1. Hospital Pharmacy Store
10.4.2. Retail Pharmacy Store
10.4.3. Online Pharmacy
10.5. Market Value Forecast by Country, 2014–2024
10.5.1. U.K.
10.5.2. Germany
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Disease Indication
10.6.2. By Product Type
10.6.3. By Distribution Channels
10.6.4. By Country
11. Asia Pacific Antiviral Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Key Trends
11.2. Market Value Forecast by Disease Indication, 2014–2024
11.2.1. Hepatitis Virus Infection
11.2.2. HIV Infection
11.2.3. Respiratory Virus Infection
11.2.4. Others
11.3. Market Value Forecast by Product Type, 2014–2024
11.3.1. Branded Drugs
11.3.2. Generic Drugs
11.4. Market Value Forecast by Distribution Channels, 2014–2024
11.4.1. Hospital Pharmacy Store
11.4.2. Retail Pharmacy Store
11.4.3. Online Pharmacy
11.5. Market Value Forecast by Country, 2014–2024
11.5.1. India
11.5.2. China
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Disease Indication
11.6.2. By Product Type
11.6.3. By Distribution Channels
11.6.4. By Country
12. Latin America Antiviral Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Policies and Regulations
12.1.3. Key Trends
12.2. Market Value Forecast by Disease Indication, 2014–2024
12.2.1. Hepatitis Virus Infection
12.2.2. HIV Infection
12.2.3. Respiratory Virus Infection
12.2.4. Others
12.3. Market Value Forecast by Product Type, 2014–2024
12.3.1. Branded Drugs
12.3.2. Generic Drugs
12.4. Market Value Forecast by Distribution Channels, 2014–2024
12.4.1. Hospital Pharmacy Store
12.4.2. Retail Pharmacy Store
12.4.3. Online Pharmacy
12.5. Market Value Forecast by Country, 2014–2024
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Disease Indication
12.6.2. By Product Type
12.6.3. By Distribution Channels
12.6.4. By Country
13. Middle East and Africa Antiviral Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Policies and Regulations
13.1.3. Key Trends
13.2. Market Value Forecast by Disease Indication, 2014–2024
13.2.1. Hepatitis Virus Infection
13.2.2. HIV Infection
13.2.3. Respiratory Virus Infection
13.2.4. Others
13.3. Market Value Forecast by Product Type, 2014–2024
13.3.1. Branded Drugs
13.3.2. Generic Drugs
13.4. Market Value Forecast by Distribution Channels, 2014–2024
13.4.1. Hospital Pharmacy Store
13.4.2. Retail Pharmacy Store
13.4.3. Online Pharmacy
13.5. Market Value Forecast by Country, 2014–2024
13.5.1. South Africa
13.5.2. GCC Countries
13.5.3. Rest of Middle East and Africa
13.6. Market Attractiveness Analysis
13.6.1. By Disease Indication
13.6.2. By Product Type
13.6.3. By Distribution Channels
13.6.4. By Country
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company – 2016 (Estimated)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. AbbVie, Inc.
14.3.1.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.1.2 Financial Overview
14.3.1.3 Product Portfolio
14.3.1.4 SWOT Analysis
14.3.1.5 Strategic Overview
14.3.2. Bristol-Myers Squibb Company
14.3.2.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.2.2 Financial Overview
14.3.2.3 Product Portfolio
14.3.2.4 SWOT Analysis
14.3.2.5 Strategic Overview
14.3.3. Cipla, Inc.
14.3.3.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.3.2 Financial Overview
14.3.3.3 Product Portfolio
14.3.3.4 SWOT Analysis
14.3.3.5 Strategic Overview
14.3.4. F. Hoffmann-La Roche Ltd.
14.3.4.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.4.2 Financial Overview
14.3.4.3 Product Portfolio
14.3.4.4 SWOT Analysis
14.3.4.5 Strategic Overview
14.3.5. Gilead Sciences, Inc.
14.3.5.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.5.2 Financial Overview
14.3.5.3 Product Portfolio
14.3.5.4 SWOT Analysis
14.3.5.5 Strategic Overview
14.3.6. GlaxoSmithKline plc.
14.3.6.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.6.2 Financial Overview
14.3.6.3 Product Portfolio
14.3.6.4 SWOT Analysis
14.3.6.5 Strategic Overview
14.3.7. Johnson & Johnson
14.3.7.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.7.2 Financial Overview
14.3.7.3 Product Portfolio
14.3.7.4 SWOT Analysis
14.3.7.5 Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.8.2 Financial Overview
14.3.8.3 Product Portfolio
14.3.8.4 SWOT Analysis
14.3.8.5 Strategic Overview
14.3.9. Mylan N.V.
14.3.9.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.9.2 Financial Overview
14.3.9.3 Product Portfolio
14.3.9.4 SWOT Analysis
14.3.9.5 Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1 Company Overview (HQ, Business Segments, Employee Strengths)
14.3.10.2 Financial Overview
14.3.10.3 Product Portfolio
14.3.10.4 SWOT Analysis
14.3.10.5 Strategic Overview
14.3.11. Others
List of Tables
Table 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 02: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 03: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 04: Global Antiviral Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 06: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 07: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 08: North America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 09: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 10: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 11: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 12: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 13: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 14: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 15: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 16: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 17: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024
Table 18: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 19: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 20: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
Table 21: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, by Country/ Region, 2014–2024
Table 22: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Disease Indication, 2014–2024
Table 23: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Product, 2014–2024
Table 24: Middle East & Africa Antiviral Drugs Market Size (US$ Mn) Forecast, by Distribution Channels, 2014–2024
List of Figures
Figure 01: Global Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: FDA Approvals
Figure 03: FDA Approvals
Figure 04: FDA Approvals
Figure 05: FDA Approvals
Figure 06: FDA Approvals
Figure 07: FDA Approvals
Figure 08: FDA Approvals
Figure 09: FDA Approvals
Figure 10: HIV Prevalence
Figure 11: Hepatitis c virus prevalence
Figure 12: Pipeline Analysis
Figure 13: Global Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 14: Global Hepatitis Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 15: Global HIV Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 16: Global Respiratory Virus Infection Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 17: Global Other Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 18: Antiviral Drugs Market Attractiveness Analysis, Disease Indication, 2016–2024
Figure 19: Global Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 20: Global Branded Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 21: Global Generic Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 22: Antiviral Drugs Market Attractiveness Analysis, by Product, 2016–2024
Figure 23: Global Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 24: Global Hospital Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 25: Global Retail Pharmacy Store Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 26: Global Online Pharmacy Antiviral Drugs Market Revenue (US$ Mn), 2014–2024
Figure 27: Antiviral Drugs Market Attractiveness Analysis, by Distribution Channels, 2016–2024
Figure 28: Global Antiviral Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 29: Antiviral Drugs Market Attractiveness Analysis, by Region, 2016–2024
Figure 30: North America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 31: North America Market Attractiveness Analysis, by Country, 2016–2024
Figure 32: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: North America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 34: North America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 35: North America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 36: North America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 37: North America Market Attractiveness Analysis, by Product, 2016-2024
Figure 38: North America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 39: Europe Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Europe Market Attractiveness Analysis, by Country/ Region, 2016–2024
Figure 41: Europe Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 42: Europe Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 43: Europe Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 44: Europe Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 45: Europe Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 46: Europe Market Attractiveness Analysis, by Product, 2016-2024
Figure 47: Europe Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 48: Asia Pacific Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 49: Asia Pacific Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 50: Asia Pacific Market Value Share Analysis, by Country/ Region, 2016 and 2024
Figure 51: Asia Pacific Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 52: Asia Pacific Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 53: Asia Pacific Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 54: Asia Pacific Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 55: Asia Pacific Market Attractiveness Analysis, by Product, 2016-2024
Figure 56: Asia Pacific Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 57: Latin America Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 58: Latin America Market Attractiveness Analysis, by Country/Region, 2016–2024
Figure 59: Latin America Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 60: Latin America Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 61: Latin America Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 62: Latin America Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 63: Latin America Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 64: Latin America Market Attractiveness Analysis, by Product, 2016-2024
Figure 65: Latin America Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 66: MEA Antiviral Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 67: MEA Market Attractiveness Analysis, by Country/ Region, 2016-2024
Figure 68: MEA Antiviral Drugs Market Value Share Analysis, by Country/Region, 2016 and 2024
Figure 69: Middle East & Africa Antiviral Drugs Market Value Share Analysis, Disease Indication, 2016 and 2024
Figure 70: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by Product, 2016 and 2024
Figure 71: Middle East & Africa Antiviral Drugs Market Value Share Analysis, by distribution Channels, 2016 and 2024
Figure 72: Middle East & Africa Market Attractiveness Analysis, by Disease Indication, 2016-2024
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Product, 2016-2024
Figure 74: Middle East & Africa Market Attractiveness Analysis, by Distribution Channels, 2016-2024
Figure 75: Global Antiviral Drugs Market Share Analysis, by Company, (2015)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Antiviral Drugs Market Insights, 2016-2024
